Original StudyModified Glasgow Prognostic Score as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated With Nivolumab
Introduction
Nivolumab (Optivo, Ono/Bristol-Myers Squibb), a fully human IgG4 programmed death 1 antibody, is a novel targeted agent that has been available in clinical practice for the treatment of metastatic renal cell carcinoma (mRCC) since 20161 and is now being rapidly adopted in Japan. Its promising anti-tumor efficacy and manageable safety profile were demonstrated in the phase III Checkmate 025 trial.1 We have previously reported on its efficacy (objective response rate, 44%) and safety profile (serious adverse events, 10% and no treatment-related deaths) in Japanese patients with mRCC.2
In real-world clinical practice, it is important to identify biomarkers that enable us to predict the response to nivolumab, as this improves our capacity for stratification of patients with mRCC. Currently, some reports have suggested that systemic inflammation is associated with disease development and progression.3,4 Inflammation biomarkers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio could shed light on the prognosis of patients with mRCC receiving nivolumab therapy.5,6 The modified Glasgow prognostic score (mGPS), a scoring system incorporating serum albumin and CRP, has been reported to reflect systemic inflammation and nutritional status and is considered to be a prognostic factor for several cancers treated through surgery or chemotherapy, including bladder cancer, upper tract urothelial carcinoma, pancreatic cancer, colorectal cancer, and RCC.7, 8, 9, 10 In patients with mRCC receiving nivolumab therapy, however, its prognostic value remains unclear. To fill this gap, we evaluated the prognostic role of mGPS in patients with mRCC treated with nivolumab.
Section snippets
Study Population
The clinical and laboratory data from 45 consecutive patients with mRCC who had previously been treated with tyrosine kinase inhibitors (TKIs) before starting treatment with nivolumab between September 2013 and August 2019 at our institution were retrospectively investigated. Two patients from this cohort had been enrolled in clinical trials. Forty-two patients had target lesions at the initiation of nivolumab. This study was approved by the Institutional Review Board at the Cancer Institute
Patient Characteristics
The median follow-up period was 26.4 months (interquartile range, 16.9-30.3 months) after initiation of nivolumab. Patient characteristics are described in Table 1. Ten (22%) patients died as a result of disease progression, and the remaining 35 (78%) patients survived; among these patients, 34 (97%) and 1 (3%) were alive at least 1 year and still within 1 year after initiation of nivolumab. Nivolumab was administered as a second-line therapy in 31 patients, a third-line therapy in 11 patients,
Discussion
We previously demonstrated the therapeutic outcomes and safety profiles of nivolumab after TKI in Japanese patients with mRCC in real-world clinical practice.2 In this study, we reported that mGPS was the most significant prognostic factor for OS in patients with mRCC treated with nivolumab. To the best of our knowledge, this is the first report to show that mGPS is an effective prognostic biomarker for the outcome of nivolumab therapy for mRCC. Although the efficacy of nivolumab therapy for
Disclosure
T. Yuasa has received remuneration for lectures from Astellas, Sanofi Japan, Pfizer Japan, Novartis Pharma Japan, Ono Pharma, Bristol-Myers Squibb Japan, Janssen Pharmaceutical K.K. Japan, MSD Japan, and Daiichi-Sankyo. The remaining authors have stated that they have no conflicts of interest.
CRediT authorship contribution statement
Ryo Fujiwara: Conceptualization, Data curation, Formal analysis, Writing - original draft, Writing - review & editing. Kosuke Takemura: Data curation, Formal analysis, Writing - review & editing. Motohiro Fujiwara: Supervision, Writing - review & editing. Takeshi Yuasa: Conceptualization, Writing - review & editing. Shotaro Yasuoka: Writing - review & editing. Yoshinobu Komai: Writing - review & editing. Noboru Numao: Writing - review & editing. Shinya Yamamoto: Writing - review & editing.
Acknowledgments
This work was partly supported by the Smoking Research Foundation and JSPS KAKENHI Grant Number 16K11035 (T.Y.).
References (21)
- et al.
Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: results from a large multicenter international collaboration
Urol Oncol
(2020) - et al.
Role of predictive value of the modified Glasgow prognostic score for later-line chemotherapy in patients with metastatic colorectal cancer
Clin Colorectal Cancer
(2018) - et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer
Cancer Treat Rev
(2013)- et al.
Cancer-related inflammation and treatment effectiveness
Lancet Oncol
(2014) - et al.
Role of interleukin-6 in the pathogenesis of multiple myeloma
Cell Biol Int
(2000) Causes and mechanisms of hypoalbuminaemia
Clin Nutr
(2001)- et al.
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
J Clin Oncol
(2009) - et al.
Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer
Int J Clin Oncol
(2020) - et al.
The role of inflammation in kidney cancer
Adv Exp Med Biol
(2014)
Cited by (8)
Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab
2022, Journal of the College of Physicians and Surgeons PakistanTumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma
2022, International Journal of Urology